KR20180008119A - A composition for treating, improving and preventing of papilloma virus infection comprising Eisenia bicyclis extract or Eisenia bicyclis fraction - Google Patents

Abstract

The present invention relates to a composition for treating or preventing human papillomavirus (HPV) infection, and specifically, to an antiviral composition capable of treating or preventing HPV infection by containing as an active ingredient an extract or fraction of Eisenia bicyclis. In addition, since the composition of the present invention is not toxic, the composition can be taken in the form of food.

Description

FIELD OF THE INVENTION The present invention relates to a composition for treating, ameliorating or preventing infections of human papillomavirus (HPV) comprising an extract of seaweed rhubarb or an extract thereof as an active ingredient, and a composition for treating, improving and preventing papilloma virus infection comprising Eisenia bicyclis extract or Eisenia bicyclis fraction.

The present invention relates to a composition capable of treating, ameliorating or preventing human papillomavirus (HPV) infection by containing an Eisenia bicyclis extract or fraction as an active ingredient.

Human papilloma virus (HPV) has been known to cause benign tumors, often called warts, infected with epithelial cells of various tissues of animals. In particular, human papilloma virus (HPV) It has been shown to be a major cause of cervical cancer, which is associated with malignant tumors in the skin and accounts for more than 90% of female uterine cancer.

Specifically, human papilloma virus (HPV) is a small DNA virus that causes a benign malignant tumor with approximately 8,000 nucleotide sequences. Up to now, more than 100 subtypes of human papilloma virus (HPV) , Approximately 90 HPV genotypes were fully analyzed. Among these types, the high-risk human papilloma virus (HPV) types (eg, HPV-16, 18, 31, 33, 35, 45, 51, 52, 56) are associated with nearly 90% of cervical cancer.

HPV-18 (12%), HPV-45 (8%) and HPV-31 (5%) were associated with HPV-16 type of cervical carcinoma infected with human papilloma virus ) Type. The cervical cancer is a cancer that can be prevented through early screening for obstetrics and gynecology, but it still ranks second in the mortality rate after breast cancer among women in the world.

Currently, there are no remedies for human papillomavirus (HPV), and vaccines are mainly used for prevention, but many side effects have also been reported. The HPV vaccine developed so far includes two worldwide, two-dose vaccine Cervarix (GSK) including HPV 16 and 18, HPV 16 and 18 and HPV 6 and 11, Vaccine Gardasil (Gardasil (TM), Merck) is present.

In addition, human papilloma virus (HPV) can not be cultured in vitro, and thus it is difficult to develop an antiviral agent against the HPV.

Thus, there is a need for a composition that is capable of treating or preventing human papillomavirus (HPV) infection that is free of side effects and that can be cultured in vitro .

Korean Patent No. 0876922 Korean Patent No. 1309538

In vitro antiviral activity of dieckol and phlorofucofuroeckol-A isolated from edible brown alga Eisenia bicyclis against murine norovirus, Algae 2015, 30 (3): 241-246 Anticancer and Cancer Preventive Properties of Marine Polysaccharides: Some Results and Prospects, Mar. Drugs 2013, 11, 4876-4901

It is an object of the present invention to provide a composition containing an extract of Eisenia bicyclis as an active ingredient to treat or prevent human papilloma virus (HPV) infection.

Another object of the present invention is to provide a composition containing an alginate Eisenia bicyclis fraction as an active ingredient to treat or prevent human papilloma virus (HPV) infection.

Yet another object of the present invention is to provide a method for treating seaweed rhizopenia bicyclis extract or fraction thereof as an active ingredient to improve or prevent human papilloma virus (HPV) infection.

Human papillomavirus (HPV) infection of a composition for the treatment or prevention of the present invention for achieving the above object rhubarb seaweed (Eisenia bicyclis ) extract as an active ingredient.

The algae rhubarb ( Eisenia bicyclis extract may be an extract obtained by immersing seaweed rhubarb ( Eisenia bicyclis ) in an extraction solvent at 20 to 26 占 폚 and then immersing it in an extraction solvent at 50 to 80 占 폚.

The algae rhubarb ( Eisenia bicyclis ) extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

The mixed solvent may be 20 to 98% by volume of an aqueous solution of methanol, ethanol, butanol or propanol.

In addition, human papillomavirus (HPV) infection of a composition for the treatment or prevention of the present invention to achieve another object above, rhubarb seaweed (Eisenia bicyclis ) fraction as an active ingredient.

The algae rhubarb ( Eisenia bicyclis ) fractions were isolated from seaweed rhizopen ( Eisenia bicyclis extract may be fractionated with dichloromethane, ethyl acetate, n-butanol or water.

The algae rhubarb ( Eisenia bicyclis ) extract may be extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

The composition may be a pharmaceutical composition for the treatment or prevention of human papilloma virus (HPV) infection.

The formulation of the pharmaceutical composition for the treatment or prevention of human papillomavirus (HPV) infection may be a liquid preparation, an external preparation for skin or an oral preparation.

In addition, human papillomavirus (HPV) infection, a food composition for prevention or improvement of the present invention to achieve another object above, rhubarb seaweed (Eisenia bicyclis ) extract or fraction thereof as an active ingredient.

The Eisenia bicyclis extract or fraction of the present invention may be used as an antiviral agent capable of treating or preventing human papillomavirus (HPV) infection or for preventing cervical cancer and laryngeal cancer due to infection with papilloma virus (HPV) Can be usefully used as pharmaceutical compositions and food compositions.

Figure 1 shows the results of in vitro studies of the rhubarb extracts and fractions prepared according to Examples 1 to 5 of the present invention This is a graph measuring the inhibitory effect of papilloma virus (HPV).

The present invention relates to a composition capable of treating or preventing human papillomavirus (HPV) infection by containing an Eisenia bicyclis extract or fraction as an active ingredient.

Hereinafter, the present invention will be described in detail.

For example, a composition capable of treating or preventing human papilloma virus (HPV) infection of the present invention contains an extract of Eisenia bicyclis as an active ingredient.

Eisenia bicyclis is a seaweed and perennial species that lives in the lower intertidal zone of Ulleungdo and Dokdo within 10m depth and is edible and used as a raw material of alginic acid. In addition, the seaweed rhizophor ( Eisenia bicyclis ) contains a large amount of minerals such as iodine and potassium.

The extract of Eisenia bicyclis is an extract obtained by mixing Eisenia bicyclis with an extraction solvent at a weight ratio of 1: 2 to 20, followed by extraction for 10 minutes to 72 hours, preferably 10 minutes to 36 hours. Preferably, the rhubarb extract is subjected to an extraction method such as cold extraction at room temperature, warm-up extraction, hot water extraction, ultrasonic extraction, and reflux-cooling extraction, more preferably the cold extraction extraction method and the hot extraction extraction method.

For example, the rhubarb extract of the present invention is immersed in an extraction solvent at 20 to 26 캜, followed by freezing for 10 minutes to 5 hours, followed by immersion in an extraction solvent at 50 to 80 캜 for 10 minutes to 5 hours, can do. At this time, the extraction solvent used for the cold beating and the extraction solvent used for warming are preferably the same extraction solvent.

As the extraction solvent for extracting the rhubarb extract, water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof may be preferably used for the treatment or prevention of human papillomavirus (HPV) infection. The mixed solvent is not particularly limited, but an extract obtained by extracting with 20 to 98% by volume of methanol, ethanol, butanol or propanol aqueous solution, more preferably 60 to 95% by volume of ethanol aqueous solution is preferable.

As another example, a composition that can treat or prevent the human papillomavirus (HPV) infection of the present invention may be a composition comprising Eisenia bicyclis ) fraction as an active ingredient.

The algae rhubarb ( Eisenia bicyclis fraction is mixed with the concentrated rhubarb extract at a concentration of 5 to 30 times (w / w), preferably 8 to 20 times (w / w), followed by a conventional fractionation process using a polar solvent and a nonpolar solvent To obtain a polar solvent fraction and a non-polar solvent fraction, respectively. Examples of the polar solvent include n-butanol and water, and examples of the non-polar solvent include dichloromethane and ethyl acetate.

The algae rhubarb ( Eisenia bicyclis ) extract or algae rhubarb ( Eisenia bicyclis ) fraction as an active ingredient may be a pharmaceutical composition.

In addition, the present invention is the rhubarb seaweed (Eisenia bicyclis ) extract or algae rhubarb ( Eisenia bicyclis ) fraction as an active ingredient.

The term "extract" or "fraction" used in reference to Eisenia bicyclis herein refers to extracts or fractions obtained by treating extraction solvents, as well as algae rhubarb ( Eisenia bicyclis ) extracts or fractions thereof. For example, the extract or fraction of Eisenia bicyclis may be prepared in powder form by further processes such as vacuum distillation and lyophilization or spray drying.

In addition, the extract or fraction of the seaweed ( Eisenia bicyclis ) of the present invention can be broadly classified into Eisenia bicyclis) of the workpiece formulated algae rhubarb (Eisenia bicyclis) to be administered to an animal, for example, rhubarb seaweed (Eisenia bicyclis ) powder. Although in the present invention the seaweed rhubarb ( Eisenia bicyclis extracts or fractions thereof, it is expected that those skilled in the art will be able to achieve the desired effects even in the form of a processed product of seaweed rhizobia ( Eisenia bicyclis ).

In the present specification, the term " comprising as an active ingredient " is meant to include an amount sufficient to achieve the efficacy or activity of the Eisenia bicyclis extract or fraction. For example, the algae rhubarb ( Eisenia bicyclis extract or fraction is used at a concentration of 10 to 1500 [mu] g / ml, preferably 100 to 1000 [mu] g / ml. Eisenia bicyclis extracts or fractions of the present invention have no adverse effects on the human body even when administered in an excessive amount as a natural product. Therefore, the extracts or fractions of Eisenia The quantitative upper limit of the bicyclis extract or fraction can be selected by a person skilled in the art within a suitable range.

The pharmaceutical composition of the present invention may be prepared by using pharmaceutically acceptable and physiologically acceptable adjuvants in addition to the above-mentioned active ingredients. Examples of the adjuvants include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, Or a flavoring agent.

The pharmaceutical composition may be formulated into a pharmaceutical composition containing at least one pharmaceutically acceptable carrier in addition to the above-described active ingredients for administration.

The pharmaceutical form of the pharmaceutical composition may be granules, powders, tablets, external preparation for skin, capsules, suppositories, liquids, syrups, juices, suspensions, emulsions, drops or injectable solutions. For example, for formulation into tablets or capsules (oral preparations), the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Also, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included as a mixture. Suitable binders include, but are not limited to, natural sugars such as starch, gelatin, glucose or beta-lactose, natural and synthetic gums such as corn sweeteners, acacia, tracker candles or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

Acceptable pharmaceutical carriers for compositions that are formulated into a liquid solution include sterile solutions suitable for the living body such as saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, One or more of these components may be mixed and used. If necessary, other conventional additives such as an antioxidant, a buffer, and a bacteriostatic agent may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.

Further, it can be suitably formulated according to each disease or ingredient, using the method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.

The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, the pharmaceutical composition of the present invention can be administered by intravenous infusion, subcutaneous injection, muscle injection, intraperitoneal injection, transdermal administration, vaginal administration, Administration.

The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, administration method, age, body weight, sex, pathological condition, food, administration time, route of administration, excretion rate and responsiveness of the patient, , A skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g / kg.

The pharmaceutical composition of the present invention can be prepared in a unit dose form by formulating it with a pharmaceutically acceptable carrier and / or excipient or can be manufactured by inserting it into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

The present invention also relates to a method for the treatment of seaweed rhizopenia ( Eisenia bicyclis extract or fraction thereof as an active ingredient. The present invention also provides a food composition for improving or preventing human papillomavirus (HPV) infection.

The food composition according to the present invention can be formulated in the same manner as the above-mentioned pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, alcoholic beverages, confectioneries, diet bars, dairy products, meat, chocolates, pizza, ram noodles, other noodles, gums, ice cream, .

The food composition of the present invention may contain, as an active ingredient, an extract or a fraction of seaweed ( Eisenia bicyclis ), as well as a component that is ordinarily added during the manufacture of a food such as protein, carbohydrate, fat, And flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings. For example, when the food composition of the present invention is prepared as a drink and a beverage, it may contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, various plant extracts, etc. in addition to the extract or fraction of seaweed ( Eisenia bicyclis ) Can be further included.

The invention rhubarb the seaweed (Eisenia bicyclis extract or fraction thereof as an active ingredient. The present invention also provides a health functional food comprising a food composition for treating or preventing human papilloma virus (HPV) infection. The health functional foods are seaweed rhubarb ( Eisenia bicyclis ) is added to food materials such as beverages, tea, spices, gum, confectionary, etc., or encapsulated, powdered or suspended, Unlike general drugs, there is an advantage that there are no side effects that can occur when a food is used as a raw material for a long time. The health functional food of the present invention thus obtained is very useful because it can be ingested routinely. The added amount of the extract of seaweed rhubarb ( Eisenia bicyclis ) in such a health functional food can not be uniformly determined depending on the kind of the health functional food to which it is added, but may be added within a range that does not deteriorate the original taste of the food, Is usually in the range of 0.01 to 50% by weight, preferably 0.1 to 20% by weight, based on the food. In the case of health functional foods in the form of pills, granules, tablets or capsules, they may be added usually in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight. In one embodiment, the health functional food of the present invention may be in the form of a pill, tablet, capsule or beverage.

The present invention is human papillomavirus (HPV) algae rhubarb (Eisenia for the manufacture of a medicament or a food for treating or preventing infection bicyclis ) extract or fractions thereof. As described above, algae rhubarb ( Eisenia bicyclis ) extract or fraction may be used for the treatment or prevention of human papillomavirus (HPV) infection.

The present invention also relates to a method of treating a mammal comprising administering to a mammal an effective amount of algae rhubarb ( Eisenia bicyclis < / RTI > extract or fraction thereof.

The term "mammal " as used herein refers to a mammal that is the subject of treatment, observation or experimentation, preferably a human.

As used herein, the term "effective amount" refers to the amount of active ingredient or pharmaceutical composition that elicits a biological or medical response in a tissue system, animal, or human, as contemplated by a researcher, veterinarian, physician or other clinician, ≪ / RTI > inducing a reduction of the symptoms of the disease or disorder. The effective amount and the administration frequency for the active ingredient of the present invention can be changed according to the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. In the prevention, treatment, or improvement of the present invention, in the case of an adult, it is preferable to administer the extract of seaweed rhubarb from a dose of 0.001 g / kg to 10 g / kg once to several times a day.

The composition comprising the extract or fraction of Eisenia bicyclis as an active ingredient in the treatment method of the present invention can be administered orally or rectally in the form of a solution or suspension of the compound of the present invention in the form of orally, rectally, intravaginally, intravenously, intraarterially, intraperitoneally, intramuscularly, Lt; RTI ID = 0.0 > and / or < / RTI > intradermal route.

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the present invention. Such variations and modifications are intended to be within the scope of the appended claims.

EXAMPLES Example 1:

After collecting 272 g of lyophilized Rhododendrons from Ulleungdo Island, they were extracted with cold water for 2 days at room temperature (24 ℃) with 1.8 L of 95% ethanol (alcohol) The mixture was extracted with warming once for a period of time, and then concentrated under reduced pressure to obtain a sulfuric ethanol extract.

Examples 2 to 5: Sulfur fraction

15.93 g of the extract of the abovementioned sulfurized ethanol obtained in Example 1 was suspended in 160 mL of distilled water, and the fractions were sequentially fractionated three times with dichloromethane, ethyl acetate and n-butanol in the same manner as in the conventional method to give a dichloromethane fraction (1.91 g, 2), ethyl acetate fraction (4.09 g, Example 3), n-butanol fraction (2.14 g, Example 4) and water fraction (7.47 g, Example 5).

<Test Example>

1. Experimental preparation

1-1. Cell preparation

293TT (human embryonic kidney cell used for HPV pseudovirus production and in vitro assay) was obtained from Schiller Lab, a cell line expressing SV40 large T antigen in 293T cells prepared by transforming adenovirus E1a) cells 37 ℃ Dulbeccos modified Eagles medium (DMEM , SH30243, Hyclone, UT, USA) in was cultured using a medium supplemented with heat inactivated 10% FBS (26140079, Hyclone, UT, USA) which is a 5% CO ₂ is fed Lt; / RTI &gt;

1-2. Production of HPV-16 pseudovirus

1-2-1. Plasmid

We produced HPV-SEAP pseudovirus for in vitro antiviral assay and HPV-Luc PV for in vivo challenge test. PC-Luc and p16L1L2 plasmids were used to produce p-SEAP and p16L1L2 plasmids and HPV-Luc PV for HPV-SEAP PV production. Each plasmid was provided from Schiller Lab (Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, USA).

1-2-2. Transfection

293TT cells were seeded in 75T flasks at 5 × 10 ⁶ cells and incubated at 37 ° C and 5% CO ₂ for 16 hours. 19 μg of p16L1 / L2 and 19 μg of pSEAP or pc-Luc plasmid were added to the Lipofectin Reagent 18292-011, Invitrogen, CA, USA). After 6 hours of transfection, the cells were replaced with complete media, and cultured at 37 ° C for 48 hours. Cells were harvested by trypsinization. The harvested cells were washed with Dulbecco's Phosphate-Buffered Saline (DPBS, 14190-250, Invitrogen, CA, USA).

1-2-3. Cell harvesting and virion maturation

After resuspension in 1 ml of DPBS, 0.2% of 5% Triton X-100 (9002-93-1, Sigma, MO, USA) and 25 mM ammonium sulfate (pH 9) (A4418, Sigma-Aldrich, (9025-65-4, Benzonas, Sigma, UK), and the cells were incubated at 37 ° C for 24 hours to maturation of the virus.

1-2-4. Salt extraction

The mature virions were cooled in ice for 5 minutes, then added with 0.17 volume of 5N NaCl and incubated for another 20 minutes on ice. Then, the virion solution was collected, transferred to an e-tube, centrifuged at 12,000 rpm for 10 minutes at 4 ° C, and the supernatant was collected by opti-prep ultracentrifugation and stored at -80 ° C.

1-2-5. refine

A gradient of 37%, 33% and 39% of DPBS / 0.8 M NaCl solution was prepared by mixing 46 ml of optiprep gradient solution with 77 ml of SIGMA density gradient medium and 23 ml of DPBS / 0.8 M NaCl 27%: 9.3 ml DPBS / 0.8 M NaCl + 13.2 ml 46% Optiprep, 33%: 6.4 ml DPBS / 0.8 M NaCl + 16.1 ml 46%, 39%: 3.4 ml DPBS / 0.8 M NaCl + 19 ml 46%). Carefully insert 39 ml, 33%, and 27% gradient solutions of 1 ml each into a 5 ml Beckman ultracentrifuge tube (361625, Beckman Coulter, USA) to prevent the layer from breaking and then load 1 ml of virion supernatant loading. The cells were centrifuged at 47,800 rpm and 16 ° C for 4 hours using an Ultracentrifuge (Optima L 90K, Beckman Coulter Ultracentrifuge, USA). The virion fractions were collected and stored at -80 ° C.

1-2-6. Titration of HPV PVs

293TT cells were seeded in 5 × 10 ³ 96-well plates and cultured at 37 ° C and 5% CO ₂ for 16 hours. After 5-fold serial dilution of HPV PVs, cells in each well were infected and cultured for 72 hours. Titer measurements of HPV-SEAP PV were performed by ascertaining the activity of secreted alkaline phosphatase (SEAP) using the Great Escape SEAP Chemiluminescence Kit (631738, Clontech, CA, USA). In addition, titer measurement of HPV-Luc PV was performed by using BioLuxGaussia Luciferase Assay Kit (0301008, New England biolabs, MA, USA). Chemiluminescent detection was performed using the Luminescence coulter (Micro beta triLux 1450, PerkinElmer, CT, USA) and the relative light units (RLU) were calculated and the HPV PV titer was calculated.

1-3. In vitro  Antiviral efficacy analysis

Screening assays and HPV inhibition assays were performed using Shaneyfelt's method (Shaneyfelt et al., 2006) and Schiller's method (Roden et al., 1996, Unckell et al., 1997, Touze et al. al., 2003, and Klasse et al., 2002). Before starting the in vitro antiviral assay, 293TT cells were seeded in 5 × 10 ³ 96-well plates and cultured at 37 ° C and 5% CO ₂ . After 16 hours, the culture medium was removed, and the extract and each fraction were diluted to a concentration of 100 ug / ml or 50 ug / ml and dispensed into cells in an amount of 100 ul. After the extract and each fraction were treated for 16 hours, the culture was removed and the cells were washed twice with PBS. Cells were infected with 100 μl of 10 ⁶ RLU / ml HPV PVs and cultured at 37 ° C and 5% CO ₂ for 48 hours. Antiviral activity was determined by the use of the Great EscapE SEAP Chemiluminescence Kit (Clontech, CA, USA). The secreted alkaline phosphatase (SEAP) activity was measured. Relative light units (RLU) values were obtained by using a luminescence coulter (Micro beta triLux 1450, PerkinElmer, CT, USA) for SEAP activity. The RLU values of the cells treated with the extract and each fraction were compared with those of the treated cells The reduction of SEAP activity was considered as an inhibition effect on HPV PVs.

Test Example  One. In vitro Papilloma virus ( HPV ) Low performance  Measure

Figure 1 shows the results of in vitro studies of the rhubarb extracts and fractions prepared according to Examples 1 to 5 of the present invention This is a graph measuring the inhibitory effect of papilloma virus (HPV).

As shown in Fig. 1, it was confirmed that both the extract of the sulphurous ethanol prepared according to Example 1 and the fractions of the sulphurous prepared according to Examples 2 to 5 were superior to the HPV16 PVs.

In particular, the rhubarb ethanol extract of Example 1 exhibited a viral inhibitory effect of 90% or more at a sample concentration of 100 μg / ml and exhibited strong activity with an IC50 value of 12.5 μg / ml or less.

In addition, among the fractions, the fractions of the dianhydrides of dichloromethane of Example 2 showed the strongest antiviral activity. Specifically, it was confirmed that the fraction had a virus inhibitory effect close to 100% at a sample concentration of 100 μg / ml or more.

Hereinafter, formulation examples of the composition containing the powder of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically described.

Formulation example  One. Sanje  Produce

500 mg of the extract powder obtained in Example 1

Lactose 100 mg

Talc 10 mg

The above components are mixed and filled in airtight bags to prepare powders.

Formulation example  2. Preparation of tablets

300 mg of the extract powder obtained in Example 1

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

Formulation example  3. Preparation of capsules

200 mg of the extract powder obtained in Example 1

Crystalline cellulose 3 mg

Lactose 14.8 mg

Magnesium stearate 0.2 mg

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

Formulation example  4. Preparation of injections

600 mg of the extract powder obtained in Example 1

180 mg mannitol

Sterile sterilized water for injection 2974 mg

Na ₂ HPO _{4 ,} 12H ₂ O 26 mg

It is prepared by the above-mentioned component content per ampoule according to the usual injection preparation method.

Formulation example  5. Liquid  Produce

4 g of the extract powder obtained in Example 1

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 g with purified water, To prepare a liquid agent.

Formulation example  6. Preparation of granules

1,000 mg of the extract powder obtained in Example 1

Vitamin mixture quantity

70 ug of vitamin A acetate

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

Vitamin B12 0.2 ug

Vitamin C 10 mg

Biotin 10 ug

Nicotinic acid amide 1.7 mg

Folic acid 50 ug

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

The composition ratio of the above-mentioned vitamins and minerals is comparatively comparatively mixed with the granules according to the preferred embodiment. However, the blending ratio may be arbitrarily changed, and the above components are mixed according to the ordinary granule preparation method, Can be prepared and used in the manufacture of a health functional food composition according to a conventional method.

Formulation example  7. Manufacture of functional beverages

 1,000 mg of the extract powder obtained in Example 1

Citric acid 1,000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added to the flask to obtain a total of 900 mL

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 DEG C for about 1 hour. The solution thus prepared was filtered and sterilized in a sterilized 2 L container, It is used in the production of the functional beverage composition of the invention.

Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.

Claims (9)

Eisenia The present invention relates to a composition for treating or preventing human papillomavirus (HPV) infection, which comprises a bicyclic extract as an active ingredient. The extract of Eisenia bicyclis according to claim 1, wherein the Eisenia bicyclis extract is an extract obtained by immersing seaweed ( Eisenia bicyclis ) in an extraction solvent at 20 to 26 ° C and immersing it in an extraction solvent at 50 to 80 ° C (HPV) infection. The composition for treating or preventing human papillomavirus (HPV) infection according to claim 1, wherein the extract of Eisenia bicyclis is extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The composition for treating or preventing HPV infection according to claim 3, wherein the mixed solvent is 20 to 98% by volume of methanol, ethanol, butanol or propanol aqueous solution. A composition for treating or preventing human papillomavirus (HPV) infection, which comprises the fraction of Eisenia bicyclis as an active ingredient. 6. The method according to claim 5, wherein the Eisenia bicyclis fraction is a human papillomavirus (HPV) infectious disease treatment characterized by fractionation of Eisenia bicyclis extract with dichloromethane, ethyl acetate, n-butanol or water. / RTI &gt; A composition for treating or preventing human papilloma virus (HPV) infection, wherein the composition of any one of claims 1 to 6 is a pharmaceutical composition for the treatment or prevention of human papilloma virus (HPV) infection. The composition for treating or preventing human papillomavirus (HPV) infection according to claim 7, wherein the pharmaceutical composition for treating or preventing infection with human papillomavirus (HPV) is a liquid preparation, a skin external preparation or an oral preparation. Eisenia The present invention relates to a food composition for improving or preventing infection with human papillomavirus (HPV), which comprises an extract or fraction of bicyclis as an active ingredient.

Images